Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)

NCT00679484 is registered in ClinicalTrials.gov with Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company as lead sponsor.

NCT NCT00679484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00679484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)
Lead sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2008
Completion date
November 30, 2009
Enrollment
400 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure, high blood b-type (or brain) natriuretic peptide (bnp) level